OncoGenex announces completion of patient enrollment in phase 3 AFFINITY trial
OncoGenex announced patient enrollment has been completed in the Phase 3 AFFINITY trial. The international, randomized, open-label Phase 3 AFFINITY trial is designed to evaluate the potential of custirsen to improve survival outcomes in approximately 630 men with metastatic CRPC. September 16, 2014